<DOC>
	<DOCNO>NCT02062515</DOCNO>
	<brief_summary>The purpose study determine whether Icotinib efficient safe treat advanced non-small cell lung cancer ( NSCLC ) patient hepatic insufficiency .</brief_summary>
	<brief_title>Icotinib Advanced Non-small Cell Lung Cancer ( NSCLC ) With Hepatic Insufficiency</brief_title>
	<detailed_description>Patients hepatic insufficiency important subgroup receive EGFR TKIs . Phase I/II study show Icotinib good security . Based consideration , single-arm , open-label study design evaluate safety icotinib 125mg three time daily histologically cytologically confirm NSCLC patient hepatic insufficiency .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis IIIB/IV stage NSCLC patient suitable surgery radiotherapy ECOG performance status point ( PS ) 02 Liver function : A ( mild hepatic dysfunction ) : A1 ) total bilirubin within normal limit ( ULN ) , AST &gt; ULN ; A2 ) total bilirubin within1.01 .5 × ULN ; B ( moderate hepatic dysfunction ) : total bilirubin within1.53 .0 × ULN No malabsorption gastrointestinal disorder effect drug absorption Life expectancy : 12 week . Previous usage HER/EGFR inhibitor target molecule drug ( small molecule drug monoclonal antibody therapy ) Patients require liver shunt , stent placement , radiotherapy 2 week start study research process . Patients active hepatitis cirrhosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>